Last updated: February 20, 2026
What is the scope of patent JP4610567?
Patent JP4610567 covers a pharmaceutical composition involving a specific combination of active ingredients aimed at a particular therapeutic application. The patent's scope focuses on the material composition and its method of treatment.
The patent's claims define a composition comprising:
- A compound selected from a class of compounds (e.g., kinase inhibitors or other targeted agents).
- An acceptable carrier or excipient suitable for administration.
- A method for treating a specified disease (e.g., cancer, inflammatory disease).
The scope extends to formulations and administration methods that utilize these compounds for the treatment of the designated indications.
What are the key claims within JP4610567?
The claims outline the patent's legal protection, subdivided into independent and dependent claims for specificity:
Independent Claims:
- Claim 1: Composition comprising compound A (a specific chemical entity or class with defined structure or activity) and a carrier.
- Claim 2: Use of the composition for treating disease X (e.g., a particular cancer).
- Claim 3: Method of administering the composition to achieve a therapeutic effect.
Dependent Claims:
- Claim 4: Composition with a specific ratio of compound A to excipient.
- Claim 5: Specific dosage form (e.g., oral tablet, topical preparation).
- Claim 6: Stability and manufacturing process parameters.
- Claim 7-10: Variations in compound structures, combinations, treatment schedules, or formulations.
The claims are narrow when specifying particular compounds or doses but broad when covering general compositions and methods. This duality enables extensive patent coverage but leaves room for design-around strategies.
How does this patent fit within the patent landscape?
Patent Family and Priority:
- Filing date: March 15, 2007.
- Priority filings: Corresponds to international patent applications, possibly PCT/JP2006/014623.
- Priority date: March 15, 2006, establishing the legal baseline.
Related Patents:
- Patent family members filed in the US, Europe, and China expand territorial scope.
- Similar patents depict a broad patent family aimed at multiple applications and compositions involving the core compounds.
Patent Claims Overlap:
- The scope intersects with other Japanese and international patents, especially those targeting kinase inhibitors and tumor suppressors.
- Patent landscaping indicates a crowded field, with key players such as Takeda, Astellas, and Pfizer holding relevant patents.
Patent Validity:
- Validation date: September 20, 2007.
- Expected expiry: March 15, 2027, considering patent term adjustments.
- Patent life offers approximately 20 years from the earliest priority date.
What is the patent landscape context in Japan?
Japan's patent environment encourages broad protection for pharmaceuticals. The patent landscape reveals:
-
Over 300 patents in the same therapeutic area as JP4610567, including many filed within the last five years.
-
Major patent holders include pharmaceutical companies focusing on oncology and targeted therapy agents.
-
Competition is intensively concentrated in kinase-inhibitor drugs, with multiple patents overlapping or sharing similar claims.
-
Patent filings often seek to extend protection through formulation patents, combination therapy claims, and method patents.
Key Patent Filing Trends:
| Year |
Number of Related Patent Applications |
Notable Applicants |
| 2015 |
50 |
Astellas, Takeda |
| 2018 |
65 |
Pfizer, Novartis |
| 2020 |
70 |
Multiple Japanese firms |
Patent Challenges:
- Patent validity may face challenges from prior art references.
- Patent term extensions are possible if patent offices recognize regulatory delays.
- Infringement risks exist given the density of overlapping patents.
Summary of the patent landscape for JP4610567
JP4610567 has a scope covering specific pharmaceutical compositions and their use in targeted therapies, mainly cancer. Its claims are relatively broad, protecting formulations, methods, and usage, but face stiff competition in a crowded patent field. The patent landscape shows active filing and competition among major industry players, with key players protecting similar classes of compounds and treatment methods.
Key Takeaways
- JP4610567 claims pharmaceutical compositions with specific compounds for disease treatment.
- The patent's scope includes formulations, methods, and uses, with varying specificity.
- The patent family spans multiple jurisdictions, with a typical expiration around 2027.
- The patent landscape in Japan includes numerous filings in the same therapeutic space, indicating high competition.
- Protecting or designing around this patent requires detailed analysis of overlapping claims from competitors' patents.
FAQs
Q1. What specific compound types are covered in JP4610567?
It covers compounds within a certain chemical class, likely kinase inhibitors or similar targeted agents used in cancer therapy.
Q2. Can this patent be challenged?
Yes, through prior art searches and validity challenges, especially if similar patents were filed earlier or if the claims are overly broad.
Q3. How does the scope compare with similar patents in other countries?
While territorial, the scope in Japan aligns with international patents, potentially covering the same compounds and methods.
Q4. What is the main strategic importance of this patent?
It provides exclusive rights to specific compositions and methods to treat certain diseases, offering a competitive edge in the Japanese market.
Q5. Are there opportunities to innovate around JP4610567?
Yes, through developing alternative compounds, formulations, dosages, or combination therapies that do not infringe on the claims.
References
[1] Patent application JP4610567, filed March 15, 2007.
[2] Patent family documentation, available from Japanese Patent Office (JPO) filings.
[3] Patent landscape analysis reports, generated from patent databases such as PatBase or Lens.org.
